Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck Acquires Ariad Cancer Drug

by Michael McCoy
May 10, 2010 | A version of this story appeared in Volume 88, Issue 19

Merck & Co. has acquired development and worldwide commercialization rights for ridaforolimus, an Ariad Pharmaceuticals drug now in Phase III trials as a treatment for metastatic soft-tissue and bone cancers. Merck will pay Ariad $50 million up front and up to $514 million in milestone payments. The two firms started collaborating on the drug, a small-molecule inhibitor of the cell proliferation protein mTOR, in July 2007. Ariad says the deal will allow it to devote resources to two other cancer therapies in its pipeline.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.